How will issues such as disruptive innovation, precision medicine and climate change affect Australia's medicines policy going forward?
Australia's National Medicines Policy (NMP) was developed cooperatively between the government, the pharmaceutical industry, health care professionals and consumers. The NMP seeks to provide overarching policy direction around four interlinked pillars: timely access to the medicines that Australians need and at an affordable cost; medicines meeting appropriate standards of quality, safety and efficacy; quality use of medicines; and maintaining a responsible and viable medicines industry.1 The policy was finalised in 1999 and was an effective framework for the interaction of the major players in Australia's health system with respect to the quality use of medicines in Australia.1 Outcomes from the original NMP include the introduction of the National Prescribing Service (now called NPS MedicineWise), which improved health outcomes relating to the quality use of medicines;2 guiding frameworks for federal government health policy changes delivered by the Department of Health; and substantial savings to government generated by pharmaceutical innovations since the development of the NMP.3
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Department of Health and Ageing. National Medicines Policy 2000. Canberra: Commonwealth of Australia, 1999. http://www.health.gov.au/internet/main/publishing.nsf/Content/B2FFBF72029EEAC8CA257BF0001BAF3F/$File/NMP2000.pdf (viewed Nov 2018).
- 2. Weekes LM, Blogg S, Jackson S, Hosking K. NPS MedicineWise: 20 years of change. J Pharm Policy Pract 2018; 11: 19.
- 3. Litchenberg FR. The impact of pharmaceutical innovation on premature mortality, hospital separations, and cancer survival in Australia. Economic Record 2017; 93: 353.
- 4. Hoebert JM, van Dijk L, Mantel‐Teeuwisse AK, et al. National medicines policies — a review of the evolution and development processes. J Pharm Policy Pract 2013; 6: 5.
- 5. World Health Organization. Thirty‐ninth World Health Assembly: summary records of committees, Geneva, 5–16 May 1986. https://apps.who.int/iris/bitstream/handle/10665/162254/WHA39_1986-REC-3_eng.pdf?sequence=1&isAllowed=y (viewed Nov 2018).
- 6. Robertson J, Santoso B, Holloway KA, et al. Asia Pacific Conference on National Medicines Policies. Aust Prescr 2012; 36 (Suppl): S1–S56.
- 7. World Health Organization. National medicines policies [website]. WHO, 2018. http://apps.who.int/medicinedocs/static/PublicSubcollections/National-Medicines-Policies (viewed Nov 2018).
- 8. Department of Health and Ageing. Australian statistics on medicines, 1999–2000. Canberra: Commonwealth of Australia, 2003 http://www.pbs.gov.au/statistics/asm/1999-2000/asm-1999-2000.pdf (viewed Nov 2018).
- 9. Department of Health and Ageing. Expenditure and prescriptions: twelve months to 30 June 2018. Commonwealth of Australia, 2018 http://www.pbs.gov.au/statistics/expenditure-prescriptions/2017-2018/expenditure-and-prescriptions-twelve-months-to-30-june-2018.pdf (viewed Jan 2019).
- 10. Harvey K. The Pharmaceutical Benefits Scheme: history, current status and post‐election prognosis. Australian Review of Public Affairs, 2001. http://www.australianreview.net/digest/2001/11/harvey.html (viewed Nov 2018).
- 11. Complementary Medicines Australia. Australia's complementary medicines: industry snapshot 2018. Canberra: CMA, 2018. http://www.cmaustralia.org.au/resources/Documents/Australian%20Complementary%20Medicines%20Industry%20snapshot%202018_English.pdf (viewed Nov 2018).
- 12. Hixon T. Are we patients, consumers or customers? Forbes, 2015; 22 Oct. https://www.forbes.com/sites/toddhixon/2015/10/22/are-we-patients-consumers-or-customers/#2f8153cc1434 (viewed Nov 2018).
- 13. Deloitte Center for Health Solutions. The US health care market: a strategic view of consumer segmentation. Deloitte, 2012 https://www2.deloitte.com/content/dam/Deloitte/us/Documents/life-sciences-health-care/us-lshc-health-care-market-consumer-segmentation.pdf (viewed Nov 2018).
No relevant disclosures.